Research published today opens up the possibility that around 20% of breast cancer patients could benefit from drugs that have so far only been used in patients with inherited BRCA mutations. In this blog, we look at the many pieces of research that have contributed to this discovery.
The Driver Prize is presented in memory of Sir Antony Driver, who was a trustee at Breakthrough Breast Cancer from 1996 to 2000. Chosen by our trustees, the prize winner is an up-and-coming researcher at the Breast Cancer Now Toby Robins Research Centre.
We’re finding new ways to outsmart breast cancer every day but sometimes it can still feel like we’re dealing with a disease that’s always one step ahead of us. Fortunately, a new technique is giving us a better head start on cancer’s next move. By picking up potential relapses earlier and helping scientists to see how someone’s cancer is behaving on a molecular level, the ‘liquid biopsy’ is making waves in the breast cancer research world.
Inside most cells in our body is our DNA, which contains the instructions that tell cells what to do and how to behave. DNA is constantly being damaged, but our cells are usually able to fix any faults, thanks to something called the DNA Damage Response. This enables the cell to repair its damage, or alternatively, if there’s too much damage it can hit the ‘self-destruct’ button, removing itself from the body so it doesn’t cause any problems.
Every year thousands of doctors, researchers and patient advocates descend on San Antonio in Texas for the world’s biggest breast cancer research conference. Breast Cancer Now was in attendance at this year’s San Antonio Breast Cancer Symposium from 6-10th December, joining over 7,000 delegates from more than 80 countries to be the first to hear the very latest developments in breast cancer research. Here we round up the highlights.